In memory of Daniella
Why We Started Unibioscience At-Home Test Platform
We Built This for Daniella.
Some missions are born from vision. Ours was born from loss.
This is for Daniella — and for everyone who deserves the chance she was not given.
Daniella was young, full of life, and surrounded by people who loved her. When cancer took her, it was not because medicine had failed to treat her — it was because the disease had been found too late. Like so many others, she never had the chance that earlier detection might have given her.
Orhan Avur, founder and CEO of Unibioscience, made a decision in the wake of that loss — not to grieve in silence, but to act. He committed himself to building something that could change the trajectory for others: a platform that makes early cancer risk screening accessible, continuous and real.
"Cancer is not a treatment problem. It is a detection problem."
This is not just a company statement. It is a belief forged through personal experience — and a promise made in Daniella's memory.
That promise became action. In 2023, we began working on LFA-based cancer tests and biomarkers in Turkey. By March 2023, we had completed laboratory validation with 298 samples, proving that early-detection signals could be reliably identified from a simple blood test. But after Daniella's passing, and guided by the message she left behind — a message that spoke clearly about the importance of catching cancer early, of not waiting, of giving people a real chance — we made a deeper commitment. We decided to go further. Not just a test, but a platform. One that could reach anyone, anywhere, before it is too late.
This is why we are building a system designed to detect cancer risk earlier — before symptoms appear.
Centralized Testing
Traditional screening often depends on clinics, laboratories and scheduled appointments, creating significant barriers to continuous monitoring.
Most Cancers Are Detected Too Late
Today, many cancer screening pathways remain centralized, appointment-based and difficult to scale. Too many people miss the opportunity for earlier risk awareness because testing is not continuous, convenient or accessible enough.
Missed Early Signals
Early biological changes may remain unnoticed when testing is infrequent or delayed, allowing risk signals to progress before intervention.
Limited Scalability
Healthcare systems need more accessible ways to support earlier follow-up outside hospital settings to meet growing population demands.
How It Works
01
Create your profile
02
Receive test kit
03
Register on our platform and provide your initial clinical health history and documentation.
We ship a clinical-grade sampling kit directly to your preferred European mailing address.
Test at home
04
Collect your biological sample easily in the comfort and privacy of your home.
Scan & Upload with app
05
Track results
06
Register your kit through the mobile app to begin the AI analysis process.
Access your longitudinal metrics and detailed risk reports via our secure patient dashboard.
Get Insight
Longitudinal risk tracking and structured outputs give healthcare professionals a clearer view of change over time.
Your Test, Step by Step
Consult a healthcare professional for clinical follow-up and guidance.
A Scalable Infrastructure for Early Cancer Risk Detection
The Unibioscience platform combines at-home sample collection, smartphone-guided scanning, and AI-supported longitudinal risk insights into a single, scalable infrastructure.
Biological Layer
A finger-prick blood sample activates a biomarker-based lateral flow test designed to identify selected cancer-associated biological signals.
Device Validation Layer
Smartphone-assisted interpretation helps normalize real-world variability across device type, lighting, angle and user environment.
Digital Intelligence Layer
Longitudinal dashboards and AI-supported risk scoring help monitor changes over time and generate structured risk insights.
From Test Result to Longitudinal Risk Monitoring
Unibioscience turns individual test results into a structured monitoring experience. Users can view risk trends, biomarker summaries, historical results and personalized recommendations. Healthcare professionals can use structured insights to support timely follow-up.
Personalized risk score
Risk trend monitoring
AI insights and recommendations
Biomarker result overview
Test history
Secure health data management
Built on Laboratory-Stage Validation
Validated under controlled laboratory conditions using biomarker-based lateral flow assays.
298
Laboratory datasets evaluated
90–94%
Sensitivity range
85–89%
Specificity range
7
Cancer areas evaluated
Colorectal
Prostate
Ovarian
Breast
Pancreatic
Liver
Thyroid
Laboratory validation is not final clinical validation. Clinical performance must be confirmed through prospective studies in the intended-use population.
A Decentralized AI-Powered Platform
Unibioscience connects patients, healthcare providers and data infrastructure through a decentralized platform that supports longitudinal risk tracking and structured insights for follow-up.
Longitudinal risk tracking
Pattern recognition across test history
Personalized risk scoring
Structured insights for clinical follow-up
Clinical integration
Population health monitoring
The At-Home Cancer Risk Monitoring Platform
A connected system combining biomarker testing, smartphone interpretation, device normalization and AI-supported longitudinal risk insights.
01
Sample Collection
Receive your Unibioscience at-home test kit securely. Perform a simple finger-prick blood sample using our guided workflow.
04
Device Validation
Designed for real-world reliability. Our layer reduces variability from lighting and camera quality to support consistent results.
02
Test Execution
Perform the test at home in just minutes. No sample shipment required in the intended workflow.
05
AI Risk Engine
The AI-supported risk engine combines signals and historical patterns to support earlier follow-up and monitoring.
03
Smartphone Scan
Scan the cassette using a guided smartphone workflow. The platform checks image quality and supports structured interpretation.
06
Dashboard Monitoring
View risk trends, biomarker summaries and historical results in a structured monitoring experience.
The Unibioscience platform is in clinical development and is not approved for commercial use. It is intended to support early risk awareness and does not provide a definitive diagnosis. Any elevated-risk result should be confirmed through clinical evaluation and laboratory-based testing.